Keyphrases
Glioblastoma
100%
Anti-PD-1
100%
Immune Heterogeneity
100%
Intratumoral Heterogeneity
100%
Genomic Instability
20%
T Cells
20%
RNA Sequencing (RNA-seq)
20%
Expression Profile
20%
Clinical Benefit
20%
Immune Checkpoint Blockade
20%
Primary Tumor
20%
Recurrent Disease
20%
PD-1 Blockade
20%
Checkpoint Blockade
20%
Molecular Characterization
20%
Immune Landscape
20%
Whole Exome
20%
EGFR mutation
20%
Tumor Evolution
20%
Burden Profile
20%
Subclonal
20%
Immune Microenvironment
20%
Anti-PD-1 Therapy
20%
Mutation Burden
20%
Focal Amplification
20%
Regional Heterogeneity
20%
IDH-wildtype
20%
Overall Survival Time
20%
Multiplex Immunohistochemistry
20%
Tumor-immune Interaction
20%
Uniform Loss
20%
Biochemistry, Genetics and Molecular Biology
Immunity
100%
Epidermal Growth Factor Receptor
50%
Genome Instability
25%
T Cell
25%
RNA Sequencing
25%
Wild Type
25%
Overall Survival
25%
Immune Checkpoints
25%
Survival Time
25%
Exome
25%
Clonal Evolution
25%
Immune Microenvironment
25%
Immunology and Microbiology
Immunity
100%
Wild Type
25%
T Cell
25%
Exome
25%
Overall Survival
25%
Immune Checkpoint Blockade
25%
Immune Landscape
25%
Survival Time
25%
Genomic Instability
25%
RNA Sequencing
25%
Clonal Evolution
25%